

Table 1: Resistance of *Acinetobacter spp.* isolates stratified by outcome in intensive care unit patients in Vojvodina Province, Serbia, 2013-2016.

Antimicrobial agents	Isolates of <i>Acinetobacter spp.</i> (n =164)		Non-survivors (n =79)		Survivors (n =85)		p
	n tested isolates	Prevalence of resistance (%)	n tested isolates	Prevalence of resistance (%)	n tested isolates	Prevalence of resistance (%)	
Piperacillin-Tazobaktam	120	98.3	52	100	68	97.1	0.506
Ampicillin-Sulbactam	88	79.5	45	73.3	43	86.0	0.205
Ceftazidime	74	100	29	100	45	100.0	-
Cefepime	117	95.7	51	90.2	66	100.0	0.013
Gentamicin	160	98.1	79	98.7	81	97.5	1.000
Amikacin	145	96.6	69	98.6	76	94.7	0.370
Ciprofloxacin	163	100	78	100	85	100	-
Imipenem	164	97.6	79	100	85	95.3	0.122
Meropenem	164	97.6	79	100	85	95.3	0.122
Doripenem	50	100	30	100	20	100	-
Tobramycin	87	60.9	45	62.2	42	59.5	0.862
Trimethoprim-Sulfamethoxazole	32	93.8	21	90.5	11	100	0.534
Colistin	147	0,0	74	0,0	73	0,0	-

A p value <0.005 is considered significant (**bold**), n: number.